{"id":"canagliflozin-jnj-28431754","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Genital mycotic infections"},{"rate":"8-12","effect":"Urinary tract infections"},{"rate":"5-10","effect":"Polyuria"},{"rate":"5-8","effect":"Thirst"},{"rate":"0.1-0.5","effect":"Diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL2048484","moleculeType":"Small molecule","molecularWeight":"444.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, canagliflozin allows glucose to be excreted in the urine rather than reabsorbed into the bloodstream, thereby reducing hyperglycemia. This mechanism is independent of insulin secretion or action, making it effective across different stages of type 2 diabetes.","oneSentence":"Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing reabsorption of glucose and promoting urinary glucose excretion to lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:45.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01512849","phase":"PHASE1","title":"A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-01","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01387737","phase":"PHASE3","title":"Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1299},{"nctId":"NCT01022112","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":383},{"nctId":"NCT01413204","phase":"PHASE3","title":"Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-07","conditions":"Type 2 Diabetes Mellitus","enrollment":272},{"nctId":"NCT03170518","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-07-21","conditions":"Diabetes Mellitus, Type 2","enrollment":171},{"nctId":"NCT04252287","phase":"PHASE3","title":"A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-03-10","conditions":"Heart Failure","enrollment":476},{"nctId":"NCT04288778","phase":"PHASE4","title":"A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Private Limited","startDate":"2020-11-25","conditions":"Diabetes Mellitus","enrollment":276},{"nctId":"NCT02065791","phase":"PHASE3","title":"Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-17","conditions":"Diabetes Mellitus, Type 2, Diabetic Nephropathy","enrollment":4401},{"nctId":"NCT03267576","phase":"PHASE4","title":"An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-27","conditions":"Diabetes Mellitus, Type 2","enrollment":64},{"nctId":"NCT01756404","phase":"PHASE1","title":"Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-06-14","conditions":"Healthy","enrollment":80},{"nctId":"NCT01989754","phase":"PHASE4","title":"A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-16","conditions":"Diabetes Mellitus, Type 2, Albuminuria","enrollment":5813},{"nctId":"NCT01032629","phase":"PHASE3","title":"CANVAS - CANagliflozin cardioVascular Assessment Study","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-12-09","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors","enrollment":4330},{"nctId":"NCT02009488","phase":"PHASE1","title":"Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-08","conditions":"Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT01809327","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-06-04","conditions":"Diabetes Mellitus, Type 2","enrollment":1186},{"nctId":"NCT02000700","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":17},{"nctId":"NCT01939496","phase":"PHASE4","title":"Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-10","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":171},{"nctId":"NCT00968812","phase":"PHASE3","title":"CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1452},{"nctId":"NCT02025907","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":218},{"nctId":"NCT01748526","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-08","conditions":"Healthy","enrollment":16},{"nctId":"NCT01787357","phase":"PHASE1","title":"A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-06","conditions":"Healthy","enrollment":60},{"nctId":"NCT01756417","phase":"PHASE1","title":"A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-10","conditions":"Healthy","enrollment":18},{"nctId":"NCT01791231","phase":"PHASE1","title":"A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-08","conditions":"Healthy","enrollment":6},{"nctId":"NCT02220218","phase":"PHASE1","title":"Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-08","conditions":"Healthy","enrollment":2},{"nctId":"NCT01483781","phase":"PHASE1","title":"A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-12","conditions":"Diabetes Mellitus, Type 2, Plasma Volume","enrollment":36},{"nctId":"NCT02039258","phase":"PHASE1","title":"Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT02071368","phase":"PHASE1","title":"A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Healthy","enrollment":3},{"nctId":"NCT01195324","phase":"PHASE1","title":"A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT00963768","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-06","conditions":"Diabetes Mellitus, Type 2","enrollment":116},{"nctId":"NCT01157000","phase":"PHASE1","title":"A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-05","conditions":"Healthy","enrollment":9},{"nctId":"NCT02039245","phase":"PHASE1","title":"Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT01064414","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2, Renal Insufficiency","enrollment":272},{"nctId":"NCT00642278","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-04","conditions":"Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent","enrollment":451},{"nctId":"NCT01665638","phase":"PHASE1","title":"Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-09","conditions":"Healthy","enrollment":10},{"nctId":"NCT01177163","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-05","conditions":"Diabetes Mellitus, Type 2","enrollment":29},{"nctId":"NCT01759576","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-03","conditions":"Renal Insufficiency, Healthy","enrollment":40},{"nctId":"NCT01128985","phase":"PHASE1","title":"A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2","enrollment":39},{"nctId":"NCT01186588","phase":"PHASE1","title":"A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-08","conditions":"Healthy, Hepatic Insufficiency","enrollment":24},{"nctId":"NCT00650806","phase":"PHASE2","title":"A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-05","conditions":"Obesity","enrollment":376},{"nctId":"NCT01454622","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-09","conditions":"Healthy","enrollment":64},{"nctId":"NCT01381887","phase":"PHASE1","title":"A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-06","conditions":"Diabetes Mellitus, Type 2","enrollment":37},{"nctId":"NCT01821027","phase":"PHASE1","title":"A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-08","conditions":"Healthy","enrollment":22},{"nctId":"NCT01459094","phase":"PHASE1","title":"Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT01707316","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06","conditions":"Healthy","enrollment":15},{"nctId":"NCT01508195","phase":"PHASE1","title":"A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-01","conditions":"Healthy","enrollment":64},{"nctId":"NCT01508182","phase":"PHASE1","title":"A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-01","conditions":"Healthy","enrollment":64},{"nctId":"NCT01733108","phase":"PHASE1","title":"A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-07","conditions":"Healthy","enrollment":29},{"nctId":"NCT01281579","phase":"PHASE1","title":"A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-01","conditions":"Healthy","enrollment":27},{"nctId":"NCT01718652","phase":"PHASE1","title":"A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-02","conditions":"Healthy","enrollment":18},{"nctId":"NCT01463774","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09","conditions":"Healthy","enrollment":74},{"nctId":"NCT01714206","phase":"PHASE1","title":"A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2009-06","conditions":"Healthy","enrollment":18},{"nctId":"NCT01714193","phase":"PHASE1","title":"A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-02","conditions":"Healthy","enrollment":30},{"nctId":"NCT01294631","phase":"PHASE1","title":"A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-03","conditions":"Healthy","enrollment":30},{"nctId":"NCT01343290","phase":"PHASE1","title":"The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT01518712","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-09","conditions":"Healthy","enrollment":64},{"nctId":"NCT01463228","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09","conditions":"Healthy","enrollment":83},{"nctId":"NCT01340677","phase":"PHASE1","title":"A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-05","conditions":"Healthy","enrollment":24},{"nctId":"NCT01428284","phase":"PHASE1","title":"A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-08","conditions":"Healthy","enrollment":14},{"nctId":"NCT01173549","phase":"PHASE1","title":"A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT01177150","phase":"PHASE1","title":"A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Healthy","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-28431754"],"phase":"phase_3","status":"active","brandName":"Canagliflozin (JNJ-28431754)","genericName":"Canagliflozin (JNJ-28431754)","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing reabsorption of glucose and promoting urinary glucose excretion to lower blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}